Humacyte (HUMA) Stock Price, News & Analysis

Company Overview

Humacyte, Inc. is a biotechnology company developing and manufacturing bioengineered human tissues for use in regenerative medicine. Its technology platform is designed to produce off-the-shelf, implantable tissues that can be stored and transported for use when needed, potentially reducing reliance on tissue obtained directly from patients or human donors.

The company’s primary product is SYMVESS, an acellular tissue-engineered vascular graft designed to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in adults with extremity arterial injuries requiring vascular replacement when an appropriate vein is unavailable. Humacyte has also investigated its vascular graft technology for applications including arteriovenous access for hemodialysis, vascular trauma, peripheral arterial disease, and pediatric heart surgery.

Humacyte was founded in 2004 by Dr. Laura Niklason, a physician-scientist and biomedical engineer, who serves as the company’s chief executive officer. The company is headquartered in Durham, North Carolina, and has conducted development and clinical activities primarily in the United States, with additional research involving international sites and collaborators.

Key Stats

• Today's Range: $0.39 to $0.45
• 50-Day Range: $0.41 to $0.74
• 52-Week Range: $0.39 to $1.90
• Volume: 8.58 million shs
• Average Volume: 4.10 million shs
• Market Capitalization: $112.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.68
• Consensus Rating: Moderate Buy

Humacyte Stock Analysis - MarketRank™

Humacyte scored higher than 58% of companies evaluated by MarketBeat, and ranked 426th out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Humacyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Humacyte has a consensus price target of $5.68, representing about 1,301.1% upside from its current price of $0.41.

Amount of Analyst Coverage

Humacyte has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Humacyte are expected to grow in the coming year, from ($0.40) to ($0.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Humacyte is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Humacyte is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Humacyte has a P/B Ratio of 20.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.92% of the float of Humacyte has been sold short.

Short Interest Ratio / Days to Cover

Humacyte has a short interest ratio ("days to cover") of 7.31.

Change versus previous month

Short interest in Humacyte has recently decreased by 7.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Humacyte does not currently pay a dividend.

Dividend Growth

Humacyte does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.46

News Sentiment

Humacyte has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Humacyte this week, compared to 4 articles on an average week.

Search Interest

Only 8 people have searched for HUMA on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Humacyte insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.10% of the stock of Humacyte is held by insiders.

Percentage Held by Institutions

44.71% of the stock of Humacyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/11/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:HUMA
• CIK: 1818382
• Web: www.humacyte.com
• Phone: 919-313-9633
• Fax: N/A
• Employees: 184
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Humacyte: $5.68
• High Price Target: $25.00
• Low Price Target: $0.50
• Potential Upside/Downside: +1,301.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$40.83 million
• Net Margins: -4,556.29%
• Pretax Margin: -4,560.82%
• Return on Equity: -983.32%
• Return on Assets: -88.84%

Debt

• Debt-to-Equity Ratio: 2.07
• Current Ratio: 6.21
• Quick Ratio: 5.74

Sales & Book Value

• Annual Sales: $2.04 million
• Price / Sales: 55.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: 20.27

Miscellaneous

• Outstanding Shares: 277,800,000
• Free Float: 269,186,000
• Market Cap: $112.59 million
• Optionable: Optionable
• Beta: 2.44